NASDAQ:ICPT Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$19.00▼$19.0050-Day Range$18.20▼$19.0052-Week Range$8.82▼$21.86VolumeN/AAverage Volume1.36 million shsMarket Capitalization$794.77 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock Analysis Get Intercept Pharmaceuticals alerts: Email Address Intercept Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainability-2.13Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.04) to $1.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.38 out of 5 starsMedical Sector905th out of 936 stocksBiotechnology Industry9th out of 11 stocks 1.0 Analyst's Opinion Consensus RatingIntercept Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageIntercept Pharmaceuticals has received no research coverage in the past 90 days.Read more about Intercept Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ICPT. Previous Next 0.0 Dividend Strength Dividend YieldIntercept Pharmaceuticals does not currently pay a dividend.Dividend GrowthIntercept Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntercept Pharmaceuticals has received a 53.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Intercept Pharmaceuticals is -2.13. Previous Next N/A News and Social Media Coverage Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intercept Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Intercept Pharmaceuticals is held by insiders.Percentage Held by Institutions83.81% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intercept Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($1.04) to $1.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intercept Pharmaceuticals is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intercept Pharmaceuticals is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntercept Pharmaceuticals has a P/B Ratio of 11.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Intercept Pharmaceuticals Stock (NASDAQ:ICPT)Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..Read More Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report ICPT Stock News HeadlinesMay 29, 2024 | finance.yahoo.comIntercept Announces New Data to be Presented at the European Association for the Study of the Liver (EASL) Congress 2024March 21, 2024 | msn.com89bio gains 47% on topline data for NASH candidateJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.February 29, 2024 | globenewswire.comIntercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBCNovember 13, 2023 | finance.yahoo.comIntercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023November 10, 2023 | finance.yahoo.comIntercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023November 8, 2023 | finance.yahoo.comAlfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.November 2, 2023 | msn.comIntercept Pharmaceuticals (ICPT) Price Target Increased by 6.63% to 19.38July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.October 31, 2023 | finance.yahoo.comWill Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should KnowOctober 27, 2023 | finance.yahoo.comStocks to Sell: 7 Overbought Companies You Ought to Dump Right NowOctober 11, 2023 | finance.yahoo.comIntercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years agoOctober 5, 2023 | msn.comIntercept Pharmaceuticals (ICPT) Price Target Increased by 21.49% to 18.17September 28, 2023 | msn.comIntercept Pharma unlikely to see rival offers, other roadblocks, analysts saySeptember 28, 2023 | msn.comCanaccord Genuity Downgrades Intercept Pharmaceuticals (ICPT)September 27, 2023 | markets.businessinsider.comIntercept Pharma Acquisition by Alfasigma: A Strategic Move and Fair Value AssessmentSeptember 27, 2023 | proactiveinvestors.comIntercept Pharmaceuticals stock soars on Alfasigma acquisition dealSeptember 26, 2023 | msn.comCanaccord cuts Intercept to hold, calls Alfasigma deal "best possible outcome"See More Headlines Receive ICPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/02/2023Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ICPT CUSIP45845P10 CIK1270073 Webwww.interceptpharma.com Phone(646) 747-1000Fax646-747-1001Employees341Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$19.00 Low Stock Price Target$19.00 Potential Upside/Downside0.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$221.82 million Net Margins-19.39% Pretax Margin-18.09% Return on Equity-77.48% Return on Assets-11.99% Debt Debt-to-Equity Ratio3.12 Current Ratio4.22 Quick Ratio2.52 Sales & Book Value Annual Sales$285.71 million Price / Sales2.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book11.05Miscellaneous Outstanding Shares41,830,000Free Float39,192,000Market Cap$794.77 million OptionableOptionable Beta0.88 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Jerome B. Durso (Age 55)President, CEO & Director Comp: $1.37MMr. Andrew Saik (Age 54)Chief Financial Officer Comp: $888.6kMr. Jared M. Freedberg J.D. (Age 55)General Counsel Comp: $812.55kMs. Linda M. Richardson (Age 59)Executive VP & Chief Commercial Officer Comp: $837.73kDr. M. Michelle Berrey M.D. (Age 56)M.P.H., President of Research & Development and Chief Medical Officer Comp: $1.12MMr. Rocco Venezia (Age 47)Chief Accounting Officer & Treasurer Comp: $660.62kMr. Nareg SagherianExecutive Director of Global Investor RelationsMr. David Ford (Age 53)Chief Human Resources Officer Comp: $434.9kDr. Mark Pruzanski M.D. (Age 55)Founder, Advisor & Director Comp: $1.3MPaul NitschmannSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsEnanta PharmaceuticalsNASDAQ:ENTAZogenixNASDAQ:ZGNXConstellation PharmaceuticalsNASDAQ:CNSTAmicus TherapeuticsNASDAQ:FOLDGeronNASDAQ:GERNView All Competitors ICPT Stock Analysis - Frequently Asked Questions How were Intercept Pharmaceuticals' earnings last quarter? Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) issued its quarterly earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.42. The business's quarterly revenue was up 16.6% on a year-over-year basis. What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO? 32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees. What other stocks do shareholders of Intercept Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA) and Micron Technology (MU). This page (NASDAQ:ICPT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intercept Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intercept Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
